Genedrive - Capital Network: FY 2017 Preliminary results: HepC test launch in sight
Published: 03:36 17 Oct 2017 EDT
KEY INVESTOR MESSAGES
- Commercial launch of Genedrive® Hepatitis C (HCV) test expected to start in the coming quarters (African markets)
- Collaboration with the US Defense Department (bio-hazard program) to generate further income in the current fiscal year
- Re-launch of Genedrive® MTB (tuberculosis) test in India is being reassessed
- Divestment options for the Services business are being pursued
- Cash position of £4.2mln as of 30 September 2017
Executive summary
UPCOMING MILESTONES
Over the next 6-12 months we expect genedrive to report significant business progress, particularly related to:
- The launch of Genedrive® HCV test in several African markets, following the distribution agreement signed with Sysmex Europe
- Reassessment of the commercial strategy for Genedrive® MTB test in India
- Potential divestment of the Services business
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities,...
FOR OUR FULL DISCLAIMER CLICK HEREThis document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.
Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO
FOR OUR FULL DISCLAIMER CLICK HERE